SNTI

+ Watchlist + Portfolio

Senti Biosciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.46
52-Week Range: $0.33 – $2.88
Market Cap: $13.58M
P/E (TTM): —
EPS (TTM): -1.69
Dividend Yield: —

Advanced Metrics

Price/Book: 5.32
PEG Ratio: —
Return on Equity: -466.46%
Return on Assets: -65.57%
Gross Margin: 0.00%
Operating Margin: -79370.59%
Profit Margin: 0.00%
Current Ratio: 0.82
Debt/Equity: —
Total Debt: $20.23M
Free Cash Flow: $-19.62M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $28.18M

SNTI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$3.29M	$1.98M	$0.00	$22.00K
Research & Development	$28.14M	$32.15M	$34.36M	$37.59M
Selling, General & Admin	$37.63M	$34.87M	$23.51M	$23.43M
Operating Expenses	$65.37M	$68.74M	$60.73M	$63.75M
Operating Income	-$62.08M	-$66.77M	-$60.73M	-$63.73M
EBITDA	-$58.16M	-$61.34M	-$56.89M	-$60.09M
Pretax Income	-$49.66M	-$83.41M	-$52.79M	-$61.44M
Net Income	-$58.21M	-$71.06M	-$52.79M	-$61.44M
Diluted EPS	-22.30	-16.01	-12.03	-2.73
Diluted Shares	2.61M	4.44M	4.60M	22.48M

SNTI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$57.62M	$35.93M	$48.28M	$16.42M
Receivables	$626.00K	$17.70M	$1.80M	$1.59M
Current Assets	$102.58M	$71.20M	$58.96M	$23.27M
Total Assets	$180.79M	$119.48M	$97.84M	$51.22M
Current Liabilities	$18.05M	$12.67M	$13.15M	$13.97M
Total Debt	$37.09M	$37.67M	$33.54M	$28.89M
Total Liabilities	$53.53M	$52.57M	$72.19M	$45.63M
Retained Earnings	-$173.29M	-$244.34M	-$297.13M	-$358.57M
Shareholders' Equity	$127.26M	$66.91M	$25.65M	$5.59M
Working Capital	$84.53M	$58.53M	$45.81M	$9.30M

SNTI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$34.90M	-$52.40M	-$41.40M	-$43.44M
Capital Expenditure	-$41.37M	-$12.04M	-$26.00K	-$196.00K
Free Cash Flow	-$76.27M	-$64.43M	-$41.42M	-$43.64M
Depreciation & Amortisation	$3.92M	$5.43M	$3.84M	$3.64M
Stock-Based Compensation	$16.39M	$9.67M	$1.75M	$5.71M
Investing Cash Flow	-$81.96M	$30.08M	$34.00K	-$184.00K
Financing Cash Flow	$118.55M	$779.00K	$53.73M	$11.76M
Net Change in Cash	$1.70M	-$21.54M	$12.37M	-$31.87M

SNTI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$22.00K	$16.00K
Research & Development	$9.28M	$10.03M	$10.52M	$7.76M	$5.28M
Selling, General & Admin	$6.42M	$6.08M	$5.75M	$5.18M	$5.76M
Operating Expenses	$16.40M	$16.80M	$16.95M	$13.61M	$11.51M
Operating Income	-$16.40M	-$16.80M	-$16.95M	-$13.58M	-$11.50M
EBITDA	-$15.47M	-$14.78M	-$16.27M	-$12.69M	-$10.81M
Pretax Income	-$14.11M	-$14.73M	-$18.13M	-$14.47M	-$4.22M
Net Income	-$14.11M	-$14.73M	-$18.13M	-$14.47M	-$4.22M
Diluted EPS	-1.41	-0.56	-0.69	-0.53	-0.14
Diluted Shares	10.01M	26.08M	26.23M	27.38M	30.97M

SNTI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$33.80M	$21.58M	$12.24M	$16.42M	$8.94M
Receivables	$2.22M	$3.69M	$1.74M	$1.59M	$765.00K
Current Assets	$45.21M	$32.52M	$18.16M	$23.27M	$14.79M
Total Assets	$82.78M	$68.54M	$52.69M	$51.22M	$38.24M
Current Liabilities	$10.73M	$9.99M	$12.03M	$13.97M	$14.27M
Total Debt	$32.45M	$31.31M	$30.12M	$28.89M	$19.14M
Total Liabilities	$44.92M	$43.89M	$44.56M	$45.63M	$35.68M
Retained Earnings	-$311.25M	-$325.98M	-$344.11M	-$358.57M	-$362.79M
Shareholders' Equity	$37.86M	$24.65M	$8.12M	$5.59M	$2.56M
Working Capital	$34.49M	$22.53M	$6.13M	$9.30M	$522.00K

SNTI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$14.05M	-$13.07M	-$9.45M	-$6.88M	-$7.48M
Free Cash Flow	-$14.05M	-$13.27M	-$9.45M	-$6.88M	-$7.48M
Depreciation & Amortisation	$926.00K	$2.02M	-$200.00K	$893.00K	$688.00K
Stock-Based Compensation	$1.20M	$1.53M	$1.55M	$1.43M	$1.31M
Investing Cash Flow	$0.00	-$184.00K	$0.00	$0.00	$114.00K
Financing Cash Flow	-$414.00K	$1.01M	$124.00K	$11.04M	-$118.00K
Net Change in Cash	-$14.46M	-$12.25M	-$9.32M	$4.17M	-$7.49M

Market Snapshot

About

Senti Biosciences is a clinical-stage biotechnology company developing next-generation cell and gene therapies using synthetic biology. The company designs programmable cellular therapies that can sense disease-specific signals and respond with precision therapeutic action. Senti is advancing multiple programs in oncology and immunology.